•Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
•Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease
•Characterizing Healthcare Disparities, Utilization, and Trends of Inflammatory Bowel Disease in Transgender and Nonbinary Patients: A Population-Based Study
•Recipients' native bacteria determine the outcome of FMT treatment in inflammatory bowel disease
•Trends in the disease burden of inflammatory bowel disease among the working-age population (20-64 years) from 1990 to 2021: a population-based study